Treatment of ocular disease

Details Treatment of ocular disease Treatment of ocular disease

2006-08-01

2006-08-01

Sheikh, Humera N. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S400000, C424S427000, C424S428000

Reexamination Certificate

active

07083802

ABSTRACT:
A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 μg/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/ml to about 200 μg/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

REFERENCES:
patent: 4079038 (1978-03-01), Choi et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4131648 (1978-12-01), Choi et al.
patent: 4138344 (1979-02-01), Choi et al.
patent: 4180646 (1979-12-01), Choi et al.
patent: 4304767 (1981-12-01), Heller et al.
patent: 4946931 (1990-08-01), Heller et al.
patent: 5294604 (1994-03-01), Nussenblatt et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5411952 (1995-05-01), Kaswan
patent: 5457182 (1995-10-01), Wiederrecht et al.
patent: 5770607 (1998-06-01), Honbo et al.
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5952371 (1999-09-01), Baker et al.
patent: 5968543 (1999-10-01), Heller et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6179817 (2001-01-01), Zhong
patent: 6238799 (2001-05-01), Opolski
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6306422 (2001-10-01), Batich et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6350442 (2002-02-01), Garst
patent: 6413536 (2002-07-01), Gibson et al.
patent: 6436906 (2002-08-01), Or et al.
patent: 6440942 (2002-08-01), Or et al.
patent: 6462026 (2002-10-01), Or et al.
patent: 6462071 (2002-10-01), Castillejos
patent: 6482799 (2002-11-01), Tuse et al.
patent: 6489335 (2002-12-01), Peyman
patent: 6534693 (2003-03-01), Fischell et al.
patent: 6596296 (2003-07-01), Nelson et al.
patent: 6613355 (2003-09-01), Ng et al.
patent: 6617345 (2003-09-01), Gregory et al.
patent: 6667371 (2003-12-01), Ng et al.
patent: 6670398 (2003-12-01), Edwards et al.
patent: 6673807 (2004-01-01), Sakai et al.
patent: 6713081 (2004-03-01), Robinson et al.
patent: 6864232 (2005-03-01), Ueno
patent: 6872383 (2005-03-01), Ueno
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0187998 (2002-12-01), Ueno
patent: 2003/0044452 (2003-03-01), Ueno
patent: 2003/0069232 (2003-04-01), Chiou
patent: 2004/0092435 (2004-05-01), Peyman
patent: 2004/0198763 (2004-10-01), Ueno
patent: 2005/0025810 (2005-02-01), Peyman
patent: 2005/0063996 (2005-03-01), Peyman
patent: 2005/0063997 (2005-03-01), Peyman
patent: 2005/0064010 (2005-03-01), Cooper et al.
patent: 2005/0070468 (2005-03-01), Ueno
patent: 17386/88 (1991-03-01), None
patent: 20350/92 (1993-01-01), None
patent: 1333018 (2002-01-01), None
patent: 1340358 (2003-03-01), None
patent: 1456350 (2003-11-01), None
patent: 19810655 (1999-09-01), None
patent: 0532862 (1993-03-01), None
patent: 1074255 (2001-02-01), None
patent: 1142566 (2001-10-01), None
patent: 07010752 (1995-01-01), None
patent: 1997030966 (1997-02-01), None
patent: 09315954 (1997-12-01), None
patent: 10218787 (1998-08-01), None
patent: 2001064198 (2001-03-01), None
patent: WO 89/01772 (1989-03-01), None
patent: WO 99/22722 (1999-05-01), None
patent: WO 99/34830 (1999-07-01), None
patent: WO 99/42104 (1999-08-01), None
patent: WO 00/66122 (2000-11-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 03/017990 (2003-03-01), None
patent: WO 03/051385 (2003-06-01), None
patent: WO 2004/014373 (2004-02-01), None
patent: WO 2004/027027 (2004-04-01), None
patent: WO 2004/043480 (2004-05-01), None
patent: WO 2004/096261 (2004-11-01), None
patent: WO 2005/011813 (2005-02-01), None
patent: WO 2005/027906 (2005-03-01), None
patent: WO 2005/030205 (2005-04-01), None
Apel, Andrew et al.,A sybconjunctival degradable implant for cyclosporine delivery in comeal transplant therapy, Curr. Eye Res. 14:659-667 1995.
PCT,International Search Report, for PCT/2004/024054, filed Jul. 27, 2004, 7 pg.
U.S. Appl. No. 10/187,013, filed Jul. 2, 2002, Ueno,Composition for Topical Administration, published Mar. 5, 2003.
U.S. Appl. No. 10/247,220, filed Sep. 19, 2002, Peyman,Treatment of Ocular Disease, published Jan. 23 2003.
U.S. Appl. No. 10/354,083, filed Jan. 30, 2003, Ueno,Use of Macrolide Compounds for the Treatment of Dry Eye, published Jul. 10, 2003.
Goodman & Gilman, Eds.,The Pharmacological Basis of Therapeutics, 8th Edition, Pergamon Press, New York, 1990, pp. 1024-1033.
Peyman et al., Eds.,Vitreoretinal Surgical Techniques, (Martin Dunitz, London, 2001, Chapter 45, pp. 521-531.
Wise, Ed.,Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 2000, pp. 108-119, 155-209, 271-285, 510-516.
Algvere et al.,Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD, European J of Ophthalmology (1999) 9(3):217-230.
Anderson et al.,A Role for Local Inflammation in the Formation of Drusen in the Aging Eye, American Journal of Ophthalmology, vol. 134, No. 3, Sep. 2002,. pp. 411-413.
Aramant et al.,Retinal transplanatation, Science & Medicines (2000), 7:20-29.
Aron-Rosa,Pulsed Nd:YAG lasers in ophthalmology, Nd:YAG Laser Applications pp. 34-48, 1986.
Carmo et al.,Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotrocin-induced diabetes, Mediators of Inflammation (2000), 9(5):243-248.
Cicciarell et al.,Pharmacokinetics of subconjunctivally administered cylcosporine A. Local delivery prior to chemotherapy for retinoblastoma, IOVS (Mar. 15, 2001), 42(4):S332.
Costantini, LC, et al.,Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture, Experimental Neurology 164,60-70 (2000).
Das et al.,The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study, Experimental Neurology (1999), 157:58-68.
Del Cerro et al.,Histologic correlation of human neural retinal transplantation, Invest. Ophthalmology & Visual Science (2000) 41(10): 3142-3148.
Dewey,2003 PCO Update: Part 1—How the square-edged IOL prevents posterior capsular opacification, Cataract & Refractive Surgery Today, Sep. 2003, pp. 20-22.
Donnenfeld et al.,Cyclosporine provides effective treatment for dry eye, Therapeutic Updates In Ophthalmology, Special Issue, Jul. 1999, pp. 1-3.
Eneydi et al.,Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine(CsA)and dexamethasone(DEX), Investigative Ophthalmology and Visual Science, vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994 abstract.
Enyedi et al.,An intravitreal device providing sustained release of cyclosporine and dexamethasone, Current Eye Research, May 1996, vol. 15, No. 5, pp. 549-557.
Garweg et al.,Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine, Klinische Monatsblatter fur Augenheilkunde, vol. 199, No. 3, Sep. 1991, pp. 199-205.
Gilbard,EW Interview: Electrolyte balance is key to dry-eye product's success, EyeWorld, Feb. 1999, pp. 20ff.
Grisolano et al.,Retinal Toxicity Study of Intravitreal Cyclosporin, Opthalmic Surgery, Mar. 1986, 17:155-156.
Jiang et al,Comeal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats, Invest. Ophthalmology & Visual Science (1994). 35)13):4300-4308.
Karacortu et al,Lack of toxicity of intravitreally administered interferon Alpha-2a, Ophthalmic Surgery (1999) 23:833-835.
Keep et al,Introduction: Immunosuppressants as Neuroprotective Agents, Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants,

Affiliated with

Also associated with

Rating

Treatment of ocular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of ocular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ocular disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3716505